文献速递骨质疏松与代谢性骨病

双膦酸盐药物假期对骨密度与骨折风险的影响:真实世界回顾性队列研究

Impact of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk: real-world evidence from a retrospective cohort study.
PubMed 文献 · Osteoporos Int · 2026-10-12

该单中心回顾性队列研究纳入接受阿仑膦酸≥4.5年或唑来膦酸≥3次的患者,比较药物假期与持续治疗对骨密度、骨转换标志物及3年骨折发生率的影响。阿仑膦酸假期导致1年内骨密度轻中度下降、骨转换标志物升高,但骨折风险未增加;唑来膦酸假期影响极小。研究提示对骨密度充足且定期监测的选定患者,双膦酸盐药物假期是可行的。

要点

  • 阿仑膦酸假期1年内腰椎骨密度下降2.23%,总髋下降1.62%,股骨颈下降1.89%。
  • 阿仑膦酸假期后骨转换标志物升高,但至少3年仍低于治疗前水平。
  • 唑来膦酸假期1–2年骨密度与骨转换标志物变化无显著差异,骨折风险未增加。

核心结论

  • 对骨密度充足的选定患者,双膦酸盐药物假期可行,唑来膦酸较阿仑膦酸提供更持久的骨骼保护,尤其腰椎。

研究设计与样本

  • 单中心回顾性队列研究,纳入接受阿仑膦酸≥4.5年或唑来膦酸≥3次的患者,比较药物假期组与持续治疗组。
  • 阿仑膦酸假期组n=71、持续治疗组n=59;唑来膦酸假期组n=20、持续治疗组n=47。

主要发现

  • 与持续阿仑膦酸治疗相比,假期组1年内腰椎骨密度下降2.23%(95%CI:-3.70%至-0.76%),总髋下降1.62%(95%CI:-2.68%至-0.56%),股骨颈下降1.89%(95%CI:-3.49%至-0.28%)。
  • 阿仑膦酸假期组骨转换标志物1年内均显著升高,但至少3年仍低于治疗前水平。
  • 唑来膦酸两组1年腰椎骨密度变化差异为-0.47%(95%CI:-2.38%至1.43%),总髋为-1.07%(95%CI:-2.77%至0.64%),无显著差异。
  • 临床脆性骨折发生率在阿仑膦酸组间(9.9% vs. 6.8%;HR 1.45)及唑来膦酸组间(5% vs. 6.4%)均无显著差异。

临床怎么用

  • 对骨密度充足且能定期监测的选定骨质疏松患者,可考虑双膦酸盐药物假期。
  • 阿仑膦酸假期期间应每年监测骨密度和骨转换标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Bisphosphonate drug holidays can reduce rare adverse effects, but their skeletal impact is unclear. In this retrospective cohort study, ALN holiday caused modest BMD loss and BTMs rise without increased fracture risk; effects of ZOL holiday were minimal. This study suggests bisphosphonate drug holidays are safe for selected patients with regular monitoring. PURPOSE: Bisphosphonate (BP) drug holiday prevents rare adverse effects of BPs in osteoporotic patients, but its effect on bone mineral density (BMD), bone turnover markers (BTMs), and fracture risk is still unclear. This study aimed to investigate BMD/BTM variations and clinical fracture risk for patients undergoing BP drug holidays. METHODS: In this single-center retrospective cohort study, patients who received ≥4.5 years of alendronate (ALN) or ≥3 doses of zoledronate (ZOL) were included. BMD at the lumbar spine (LS), femoral neck (FN), and total hip (TH), BTMs, and 3-year fracture incidence were assessed between drug holiday (ALN: n = 71; ZOL: n = 20) and ongoing treatment groups (ALN: n = 59; ZOL: n = 47). RESULTS: Compared with ongoing ALN therapy, initiating drug holiday resulted in moderate declines in BMD at LS (-2.23%, 95% CI: -3.70% to -0.76%), TH (-1.62%, 95% CI: -2.68% to -0.56%), and FN (-1.89%, 95% CI: -3.49% to -0.28%) within 1 year. BTMs all rose significantly over 1 year, yet remained below pretreatment levels for at least 3 years. In contrast, there were no significant differences in BMD (1-year LS: -0.47%, 95% CI: -2.38% to 1.43%, TH: -1.07%, 95% CI: -2.77% to 0.64%) and BTM changes between ZOL groups at 1- and 2-year follow-up. No significant differences in clinical fragility fractures were observed between ALN groups (9.9% vs. 6.8%; HR 1.45) and ZOL groups (5% vs. 6.4%). CONCLUSION: Our findings support that BP drug holidays are feasible for selected patients with adequate BMD. ZOL conferred more sustained skeletal protection than ALN, particularly at the LS, whereas ALN discontinuation was associated with earlier and more pronounced BMD decline and BTM elevation; annual monitoring of BMD and BTMs appears particularly important during the ALN drug holiday period.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Zhang S, Wang Z, Zhou R, et al. Impact of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk: real-world evidence from a retrospective cohort study. Osteoporos Int. 2026. PMID: 42862289. doi:10.1007/s00198-026-08239-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。